Search

Author/Creator Rizzieri, D.

2. A Phase I Trial of Ipilimumab (IPI) in Patients (PTS) with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMAS) Failure. (April 2017)

Authors:
Zeidan, A.; Knaus, H.; Robinson, T.; Zeidner, J.; Blackford, A.; Duffield, A.; Rizzieri, D.; Frattini, M.; Levy, M.Y.; Schroeder, M.; Ferguson, A.; Sheldon, K.; Dezern, A.; Gojo, I.; Gore, S.; Streicher, H.; Luznik, L.; Smith, B.D.
Journal:
Leukemia research
Issue:
Volume 55(2017)Supplement 1
Page Start:
S43
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. PB1828: CADENZA: A PIVOTAL STUDY OF PIVEKIMAB SUNIRINE (IMGN632) IN PATIENTS WITH UNTREATED/FRONTLINE BPDCN. (23rd June 2022)

Authors:
Pemmaraju, N.; Martinelli, G.; Todisco, E.; Tarella, C.; Montesinos, P.; Lane, A. A.; Erba, H. P.; Sweet, K. L.; Walter, R. B.; Deconinck, E.; Wang, E. S.; Aribi, A.; Ulrikson, M. L.; Levy, M. Y.; Lebon, D.; Marconi, G.; DeAngelo, D. J.; Rizzieri, D.; Konopleva, M.; Sloss, C. M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1708
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗